SAN FRANCISCO, CA USA (UroToday.com) - This abstract was presented by Dr. Uemura and colleagues from Japan. This group reported on a randomized phase II trial to evaluate the efficacy of peptide vaccination therapy for chemotherapy-naive CRPC patients.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The primary endpoint of their study was progression-free survival, including serum PSA, with secondary endpoint being overall survival and safety. Early-stage CRPC (PSA< 10ng/ml) patients positive for HLA-A02 or A24 or A3 super family were randomized into 2 treatment groups -- peptide vaccine with low dose (1mg/day) dexamethasone (Dx) versus low dose Dx alone. Patients were vaccinated subcutaneously with 3 mg of selected peptides (max. 4 kinds) 6 times at 2-week intervals. Dx 1mg/day p.o. was started on the first day of peptide vaccination. Toxicity was assessed monthly, and immunological responses such as cytotoxic T-lymphocyte activity and clinical responses were evaluated every 3 months.
A total of 83 chemotherapy-naive CRPC patients were enrolled into the trial. Of these, 10 patients were excluded due to HLA type mismatch and exclusion criteria. Seventy-three patients were then randomized (37 in the vaccine treatment group and 36 in the Dx group). They reported a median time of 602 days to PSA failure in the vaccine group vs 210 days in the controlled arm (p < 0.001). They concluded that combination therapy of peptide vaccines and low dose dexamethasone may be a promising tool for chemotherapy-naive CRPC patients.
Highlights of a presentation by Hirotsugu Uemura at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA
Department of Urology, Kinki University Faculty of Medicine, Osaka, Japan